The site is undergoing maintenance on
If you encounter problems while ordering, please contact us at BDBCustomerService@bd.com
See More
Overview
Pre-formulated and ready-to-use reagents that leverage the BD® Horizon Dri Technology, which reduces variability and eliminates manual pipetting. Our multicolor panels demonstrate consistent use in a variety of clinical research trials and applications. The BD Horizon™ Dri Reagents are backed by innovation, based on consensus guidelines, informed by customer voice and collaborations, and supported by high-impact publications.
The reagents include:
- TBNK + CD20 Panel
- Tumor and tissue dissociation reagent (TTDR)
On This Page
TBNK + CD20 Panel
The BD Horizon™ Dri TBNK + CD20 Multicolor Panel is optimized for immune monitoring research
The panel was designed for clinical research based on key feedback from Mass General Hospital and Harvard Medical School. The addition of CD20 to standard TBNK analysis expands the utility of a very common test. This tube has been used in research and clinical trials, from monitoring immune responses to CD20 depletion therapies.
The panel:
- Characterizes T, B and NK cells
- Provides absolute counts when paired with BD Trucount™ Tubes
- Offers standardization with the all-in-one dried format, reducing variability
- Eliminates manual pipetting, increasing efficiency
- Is flexible with open channels for liquid drop-ins
| Panel Composition | ||
Format | Specificity | Clone |
FITC | CD3 | SK7 |
PE | CD16/56 | B73.1/NCAM16.2 |
PerCP-Cy5.5 | CD45 | 2D1 |
PE-Cy7 | CD4 | SK3 |
APC | CD19 | SJ25C1 |
APC-Cy7 | CD8 | SK1 |
V450 | CD20 | L27 |
The BD Horizon™ Tumor and Tissue Dissociation Reagent (TTDR) is optimized for tumor microenvironment research
The BD TTDR reagent was designed for gentle and effective dissociation of tumors and tissue for single-cell studies. It is optimized to maximize cell yields, while minimizing cell death and epitope/antigen damage.
The reagent:
- Maximizes cell yields during dissociation while minimizing cell death, epitope/antigen damage
- Dissociates a variety of tumor types to enable and empower single-cell studies
- Maintains the heterogeneity and diversity of your samples, ensuring precise results
PERFORMANCE
BD Horizon™ Dri Reagents can be used to characterize various immune subtypes and dissociate solid tumors into single cells
References
- Snowden E, Porter W, Hahn F, et al. Immunophenotyping and transcriptomic outcomes in PDX-derived TNBC tissue. Mol Cancer Res. 2017;15(4):429-438. doi: 10.1158/1541-7786.MCR-16-0286-T
- Sen M, Hahn F, Black TA, et al. Flow based single cell analysis of the immune landscape distinguishes Barrett's esophagus from adjacent normal tissue. Oncotarget. 2019;10(38):3592-3604. doi: 10.18632/oncotarget.26911
CyTM is a trademark of Global Life Sciences Solutions Germany GmbH or an affiliate doing business as Cytiva.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.